Traws Pharma Stock Surges 57.74% Amid Clinical Updates
By ATTN Desk · Editorial oversight: Sean Han
Traws Pharma, Inc. (NASDAQ: TRAW)
Introduction
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule antivirals for respiratory viral diseases. Its two lead programs are:
- Tivoxavir marboxil – a single-dose cap-dependent endonuclease inhibitor targeting H5N1 bird flu and seasonal influenza.
- Ratutrelvir – an oral main protease (Mpro) inhibitor for COVID-19 that does not require ritonavir co-administration.
Corporate Structure
- Headquarters: Newtown, Pennsylvania
- Employees: 51–200
- Formed: April 3, 2024 (merger of Onconova Therapeutics and Trawsfynydd Therapeutics)
- Executive Team:
- Iain D. Dukes, D Phil – Interim Chief Executive Officer & Executive Chairman
- Nora Brennan – Interim Chief Financial Officer
- C. David Pauza, PhD – Chief Scientific Officer
- Robert R. Redfield, MD – Chief Medical Officer
- Victor Moyo, MD – Chief Medical Officer, Oncology
- Nikolay Savchuk, PhD – Chief Operating Officer
- Board Highlights: Includes Iain Dukes, Werner Cautreels (retired CEO), James Marino, M. Theresa Shoemaker, Trafford Clarke, Jack E. Stover.
Recent Developments
- February 2025: Nasdaq confirmed compliance with Listing Rule 5550(b)(1).
- March 28, 2025: Werner Cautreels retired as CEO; Iain Dukes appointed Interim CEO.
- December 2024 & January 2025:
- Murine H5N1 model: single-dose tivoxavir marboxil demonstrated suppression of viral burden.
- Ferret H5N1 model: efficacy data for tivoxavir marboxil reported.
- March 2025: Phase 1 data for ratutrelvir presented at ICAR 2025.
- May 19, 2025 (Form 8-K): Reported Q1 2025 results and clinical updates for tivoxavir marboxil and ratutrelvir programs.
- June 3, 2025: Share price increased by 57.74% to $2.2399 on a volume of 23.8 million shares.
Financial & Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (June 3, 2025) | $2.2399 (+57.74%) |
| Volume | 23,811,492 |
| Market Cap (intraday) | $12.6 million |
| Beta (5Y Monthly) | 1.47 |
| EPS (TTM) | –27.20 |
| Price/Sales (TTM) | 19.68 |
| Price/Book (MRQ) | 1.32 |
| Cash (MRQ) | $15.94 million |
| Net Income (TTM) | –$34.61 million |
| Financing Commitments | Up to $72.6 million |
- Cash Runway: Cash of $15.9 million at the end of the most recent quarter, along with financing commitments, supports planned Phase 2 studies.
- R&D Focus: The company utilizes accelerated trial strategies for antivirals with simple dosing regimens aimed at addressing resistant strains.
Market Position & Industry Context
- Therapeutic Area: Respiratory viral diseases (influenza, bird flu, COVID-19).
- Competitive Landscape:
- Influenza inhibitors: oseltamivir, baloxavir.
- COVID-19 protease inhibitors: nirmatrelvir (Paxlovid), which requires ritonavir.
- Differentiators:
- Single-dose potential for tivoxavir marboxil.
- No requirement for ritonavir co-administration for ratutrelvir, thus reducing the risk of drug–drug interactions.
- Target Populations: Elderly, immunocompromised individuals, and other populations at increased risk for severe disease.
tl;dr
- As of March 28, 2025, Iain Dukes assumed the role of Interim CEO.
- Phase 1 data for tivoxavir marboxil (H5N1 flu) and ratutrelvir (COVID-19) support the initiation of Phase 2 trials expected in the first half of 2025.
- On June 3, 2025, the stock price increased by 57.74% to $2.2399 with 23.8 million shares traded.
- Cash on hand of $15.9 million (most recent quarter) plus financing commitments of up to $72.6 million support upcoming clinical milestones.